MiniMed™780G insulin pump system^

Advanced Hybrid Closed Loop






Ever asked yourself...

- ? When can I correct without going low?
- ? When can I eat again?
- ? Do I have to carb count?
- ? Should I keep myself high in case I go low?
- I don't want to run high, but I don't want to go low.
- ? When should I exercise?

Then maybe a Pump System is right for you!





Not all pump systems are the same

The MiniMed[™] 780G is the only system available to consistently achieve 80% time in range or higher in both clinical studies and in real-world data. ^{2,~}

MiniMed™ 780G³,4~ 81.3%



Other Systems⁵ 67.7% - 72.6%

80% time in range means over 19 hours daily spent between 3.9 and 10 mmol/L.

The results | am after!

Extra time in range with MiniMed™ 780G!



+3.1 extra hours/day



+47 extra days/year




SmartGuard[™] Technology Automation

the brains







1 Autocorrections

Can be delivered as frequently as 12 times per hour!

So I don't have to worry!

2 Meal Detection Technology

If rising glucose patterns suggest a meal, the system can automatically administer stronger correction doses to stabilise glucose levels back within range.

I can finally enjoy my food 3 Auto Basal


Real time micro basal adjustment, increases and decreases insulin every 5 minutes based on your sensor glucose.

Your choice of 3 System Targets

5.5 mmol/L

6.1 mmol/L

6.7 mmol/L





Hear from our Chief Engineer



All your data on all apps

- All pump data
- All alerts
- Dedicated Follow App



This sounds easy as!

For my peace of mind



Meal Detection[™] Technology^{7,§}

Oh wait - you forgot to bolus! If the system detects a meal (based on the rapid rise of your sugar levels), it will automatically deliver correction doses while sugar levels are rising, up to every 5 minutes, to help bring you back to target.

If your carb counts aren't exact or if you occasionally miss a meal dose, the system automatically delivers a correction dose.

Proven to improve your quality of life



way of eating⁶





Leading the way to innovation

For over 40 years Medtronic has committed to transforming diabetes care.

A history of firsts. A future of innovation. Your partner in diabetes care.

96% fewer injections with MiniMed™ 780G System#

96%



Keen to get started?

yes!



Find us here



Until there's a cure there is MiniMed™

References:

^ components sold separately. —When recommended settings of glucose target 5.5 mmol/L and active insulin time 2 hours are used in patients >15yrs. #vs multiple daily injections. *vs the 3-days infusion set MiniMed Quick-set. § Taking a bolus 15-20 minutes before a meal helps to keep blood sugar levels under control after eating. 1. 42 Factors that affect Blood Glucose - Adam Brown https://diatribs.org/42factors, October 2019. 2. Arrieta, Ochone et al. Diabetes Obes Metab. 2022;24:1370-1379. 3. Arrieta, Arcelia, et al. "Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users." Diabetes, Obesity and Metabolism 24.7 (2022): 1370-1379. 4. Choudhary, Pratik, et al. "Celebrating the data from 100,000 real-world users of the MiniMedf W80G system in Europe, Middle East, and Africa collected over 3 years: from data to clinical evidence." Diabetes Technology & Therapeutics 26.53 (2024): 32-37. 6. Edd, S. N., J., Choudhary et al. Diabetes, Obesity and Metabolism Volume 25 Number 11, 2023. 5. Alwan, Heba, et al. "Real-world evidence analysis of a hybrid closed-loop system." Journal of diabetes science and technology (2023): 19322968231185348. Kovatchev, Boris P., et al. "Biobehavioral changes following transition to automated insulin delivery: A large real-life database analysis." Diabetes Care 45.11 (2022): 263-2643. Forlenza, Gregory P., et al. "Real-world evidence of Omnipod* 5 automated insulin delivery system use in 69,902 people with Type 1 diabetes." Diabetes Technology & Therapeutics (2024). 6. Simmons J.H., McFannK.K., et al. Reliability of the Diabetes Fear of Injecting and Self-Testing Questionnaire in Pediatric Patients With Type 1 Diabetes. Diabetes Care, Volume 30, Number 4, April 2007 Nguyen, K.T., Xu, N.Y., et al. Improving the Patient Experience With Longer Wear Infusions Responsible Responsible Science and Technology 1.80 people with Type 20 people with Type 20 people with Type 30 people with Type 30 people with Type 40 people with

ALWAYS FOLLOW DIRECTIONS FOR USE

For detailed information regarding indications, contraindications, warnings, precautions, and potential adverse effects, please consult the IFU. Always consult a Health Care Professional before making treatment decisions, and to see if this product is suitable for you. For detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events, please consult the device manual. For further information, contact your local Medtronic representative. The legal manufacturer of MiniMed™ infusion sets is Unomedical a/s. Aaholmvej 1-3, Osted. 4320 Lejre, Denmark. DreaMed Diabetes is a trademark of DreaMed Diabetes, Ltd. The MiniMed™ 780G system algorithm includes technology developed by DreaMed Diabetes.

AU-DBA-2500001©2025 Medtronic Australasia Pty Ltd. All rights reserved.

2 Alma Road, Macquarie Park, NSW 2113.

Tel: +61 2 9857 9000 Fax: +61 2 9889 5167 Toll Free: 1 800 777 808

Facebook: www.facebook.MedtronicsDiabetesAUS
Youtube: Medtronic Diabetes ANZ

Instagram: @MedtronicDiabetesAUS Email: australia.diabetes@medtronic.com

